Abstract
Zusammenfassung. In der Behandlung der adulten ADHS haben sich sowohl pharmakologische Interventionen als auch psychosoziale Behandlungen als wirksam erwiesen. In der täglichen klinischen Routine wird die Behandlung jedoch weniger von den Ergebnissen klinischer Studien als von Behandlungsrichtlinien und Anforderungen nationaler Institutionen (Gemeinsamer Bundesausschuss) beeinflusst. Der Hauptaspekt dieser Vorschriften ist die Anforderung, dass ein stufenweiser Behandlungsansatz, beginnend mit niederschwelligen Interventionen, am sinnvollsten für die Behandlung bei adulten ADHS-Patienten ist. Leider gibt es bis heute fast ausschließlich klinische Studien, welche die Auswirkungen einzelner Therapiestrategien erforschen. Das gestufte Versorgungsmodell scheint noch nicht ausreichend validiert. Genau hier möchte die im Folgenden beschriebene ESCAlate-Studie ansetzen. Bei ESCAlate handelt es sich um eine randomisierte, kontrollierte Studie. Es sollen 279 Patienten im Alter zwischen 16.00 und 45.11 Jahren in das Behandlungsprogramm, welches sich in mehrere Abschnitte gliedert, aufgenommen werden. In einem ersten Behandlungsabschnitt werden die Patienten nach dem Zufallsverfahren in drei Gruppen eingeteilt: Psychoedukation im Einzelsetting (PE), Telefonassistierte Selbsthilfe (TASH) oder Wartekontrollgruppe. Alle Patienten der Wartegruppe erhalten nach dreimonatiger Wartezeit eine Behandlung mit TASH. Im zweiten Behandlungsabschnitt werden die Patienten entsprechend der Schwere ihrer persistierenden Symptome in die drei Gruppen Full-Responder, Partial-Responder und Non-Responder eingeteilt. Patienten, welche als Full-Responder eingestuft wurden erhalten ein verhaltenstherapeutisch orientiertes Coaching. Partial-Responder erhalten ebenfalls dieses Coaching, wobei in dieser Gruppe der Zufall entscheidet, ob die Patienten zusätzlich ein Neurofeedbacktraining (NF) erhalten. Non-Responder erhalten eine pharmakologische Behandlung mit Methylphenidat. Hier entscheidet ebenfalls der Zufall, ob die Patienten zusätzlich ein Neurofeedbacktraining erhalten. ESCAlate zeichnet sich durch eine relativ naturalistische Stichprobenzusammensetzung aus, da auf hochspezifische Ein- und Ausschlusskriterien verzichtet wurde, um eine Patientenstichprobe zu erhalten, die die Patienten der alltäglichen klinischen Routine in den Praxen widerspiegelt. Die Wirksamkeit einer evidenzbasierten Intervention mit gestufter Behandlung wird durch primäre (Verringerung des Schweregrads der ADHS-Symptome) und sekundäre Ergebnisse (funktionelle Ergebnisse; z.B. Lebensqualität, Ärger-Management, Steigerung des psychosozialen Wohlbefindens) untersucht. Prädiktoren für therapeutisches Ansprechen bzw. Nicht-Ansprechen werden bei jedem Schritt der Intervention evaluiert. Darüber hinaus können eventuelle geschlechtsspezifische Unterschiede untersucht werden.
Abstract. In the treatment of adult ADHD, both pharmacological interventions and psychosocial treatments have been shown to be effective. However, in day-to-day clinical routine, treatment is less influenced by the outcomes of clinical trials than by treatment guidelines and requirements of national institutions (Federal Joint Committee). The main aspect of these regulations is the requirement that a step-by-step approach, starting with low-threshold interventions, is most appropriate for treatment in adult ADHD patients. Unfortunately, almost all clinical studies investigate the effects of individual therapeutic strategies. The tiered supply model does not seem to have been sufficiently validated yet. This is exactly where the ESCAlate study described below would like to start. ESCAlate is a randomized, controlled trial. 279 patients between the ages of 16.00 and 45,11 years will be enrolled in the treatment program, which is divided into several sections. In a first stage of treatment, patients are randomized into three groups: Individualized Psychoeducation (PE), Self-Helped Telephone Assisted Self-Help (TASH), or Waiting Control Group. All patients in the waiting group receive treatment with TASH after a waiting period of three months. In the second part of the treatment, patients are divided into the three groups full responders, partial responders and non-responders according to the severity of their persistent symptoms. Patients classified as full-responders receive behavioral-oriented coaching. Partial responders also receive this coaching, whereby in this group patients can be randomized to an additionally neurofeedback training (NF). Non-responders receive pharmacological treatment with methylphenidate and can be randomized to the additionally neurofeedbacktraining. ESCAlate is characterized by a relatively naturalistic sampling composition, as it does away with highly specific inclusion and exclusion criteria in order to obtain a patient sample that reflects the patients' daily routine in the practices. The effectiveness of an evidence-based intervention with graded treatment is assessed by primary (reduction in the severity of ADHD symptoms) and secondary outcomes (functional outcomes such as quality of life, anger management, increase in psychosocial well-being). Therapeutic response/non-response predictors are evaluated at each step of the intervention. In addition, any gender differences can be investigated.
Literarur
(1993). The Spot-the-Word test: A robust estimate of verbal intelligence based on lexical decision. British Journal of Clinical Psychology, 32, 55–65.
(1998). CTQ: Childhood Trauma Questionnaire: a retrospective self-report. San Antonio, TX: Psychological Corp.
(1999). Age-related changes in quantitative EEG in attention-deficit/hyperactivity disorder. Biological Psychiatry, 46, 1690–1697.
(2002). Specificity of quantitative EEG analysis in adults with attention deficit hyperactivity disorder. Psychiatry Research, 112, 133–144.
(2015). Validation of the adult attention-deficit/hyperactivity disorder quality-of-life scale in European patients: comparison with patients from the USA. ADHD Attention Deficit and Hyperactivity Disorders, 7, 141–150.
(2005). Conceptualization and assessment of quality of life for adults with attention-deficit/hyperactivity disorder. Primary Psychiatry, 12, 58–64.
(1989). The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Research, 28, 193–213.
(1983). Hyperactive children's event-related potentials fail to support underarousal and maturational-lag theories. Archives of General Psychiatry, 40, 1243–1248.
(1996). Quantitative electroencephalographic profiles of children with attention deficit disorder. Biological Psychiatry, 40, 951–963.
(2015). Altered white matter tract property related to impaired focused attention, sustained attention, cognitive impulsivity and vigilance in attention-deficit/hyperactivity disorder. Journal of Psychiatry & Neuroscience: 40, 325.
(1998). EEG analysis in attention-deficit/hyperactivity disorder: a comparative study of two subtypes. Psychiatry Research, 81, 19–29.
(2008). Attention deficit/hyperactivity disorder: a review and update. Journal of Pediatric Nursing, 23, 345–357.
(2009). Psychoedukation und Coaching ADHS im Erwachsenenalter: Manual zur Leitung von Patienten- und Angehörigengruppen. München: Elsevier, Urban & Fischer.
(1996). Topographical analyses of attention disorders of childhood. International Journal of Neuroscience, 87, 41–61.
(2011). Cognitive behaviour therapy in medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial. BMC Psychiatry, 11, 1.
(2014). Validation of the STAXI-2: A study with prison inmates. Psychological Test and Assessment Modeling, 56, 178.
(2009). A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. The Journal of Clinical Psychiatry, 71, 754–763.
(2007). Cross–national prevalence and correlates of adult attention–deficit hyperactivity disorder. The British Journal of Psychiatry, 190402–409.
(2013). Die Symptom-Checkliste SCL-90®. Handanweisung. Göttingen: Hogrefe.
(2009). Distinct EEG effects related to neurofeedback training in children with ADHD: a randomized controlled trial. International Journal of Psychophysiology, 74, 149–157.
(2002). Epidemiologie komorbider psychischer Störungen bei Rehabilitanden mit muskuloskelettalen und kardiovaskulären Erkrankungen. Die Rehabilitation, 41, 367–374.
(1995). Differences in baseline EEG measures for ADD and normally achieving preadolescent males. Biofeedback and Self-regulation, 20, 65–82.
(2006). Neuropsychologie. Berlin: Springer.
(2005). Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication. Biological Psychiatry, 57, 1442–1451.
(2009). Increased EEG power density in alpha and theta bands in adult ADHD patients. Journal of Neural Transmission, 116, 97–104.
(1993). Corticocortical inhibition in human motor cortex. The Journal of Physiology, 471, 501.
(1999). Simultaneous EEG and EDA measures in adolescent attention deficit hyperactivity disorder. International Journal of Psychophysiology, 34, 123–134.
(1998). Quantified EEG activity in adolescent attention deficit hyperactivity disorder. Clinical Electroencephalography, 29, 37–42.
(2011). The efficacy of pharmacological versus psychotherapeutic therapies in adults with attention deficit/hyperactivity disorder (ADHD): an empirical meta-analysis. Verhaltenstherapie, 21, 229–238.
(2010). Objective measurement of motor activity during cognitive performance in adults with attention-deficit/hyperactivity disorder. Acta Psychiatrica Scandinavica, 122, 285–294.
(2009). Hyperactive-impulsive symptoms associated with self-reported sleep quality in nonmedicated adults with ADHD. Journal of Attention Disorders.
(1992). Quantitative analysis of EEG in boys with attention-deficit-hyperactivity disorder: Controlled study with clinical implications. Pediatric Neurology, 8, 30–36.
(1993). A cross-national EEG study of children with emotional and behavioral problems: a WHO collaborative study in the Western Pacific Region. Biological Psychiatry, 34, 59–65.
(2013). One size fits all? Slow cortical potentials neurofeedback. A review. Journal of Attention Disorders, 17, 393–409.
(2011). Telephone-based mental health interventions for child disruptive behavior or anxiety disorders: randomized trials and overall analysis. Journal of the American Academy of Child & Adolescent Psychiatry, 50, 1162–1172.
(2012). Prevalence of attention-deficit hyperactivity disorder in older adults in The Netherlands. The British Journal of Psychiatry, 201, 298–305.
MTA Studiengruppe (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal treatment study of children with ADHD. Archives of General Psychiatry, 56, 1073–1086.National Collaborating Centre for Mental Health (2009). Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults. Online: https://www.ncbi.nlm.nih.gov/pubmed/22420012.(2010). Evaluation of the efficacy and effectiveness of a structured disorder tailored psychotherapy in ADHD in adults: study protocol of a randomized controlled multicentre trial. ADHD Attention Deficit and Hyperactivity Disorders, 2, 203–212.
(2015). Comparison of Methylphenidate and Psychotherapy in Adult ADHD Study (COMPAS)Consortium. Effects of Group Psychotherapy, Individual Counseling,Methylphenidate, and Placebo in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 72, 1199–210.
(2007). The worldwide prevalence of ADHD: A systematic review and metaregression analysis. American Journal of Psychiatry, 164, 942–948.
(1997). Anger and anger expression in adults with high ADHD symptoms. Journal of Attention disorders, 2, 115–128.
(1985). CGI (Clinical Global Impression) scale – NIMH. Psychopharmacol Bull, 21, 839–843.
(2013). Standardisierte Skalen zur strukturierten Diagnostik der ADHS im Erwachsenenalter. Fortschritte der Neurologie· Psychiatrie, 81, 381–389.
(2012). Multiscale assessment of treatment efficacy in adults with ADHD: a randomized placebo-controlled, multi-centre study with extended-release methylphenidate. The World Journal of Biological Psychiatry, 13, 48–59.
(2012). Integrierte Diagnose der ADHS im Erwachsenenalter – IDA. Iserlohn: Medice.
(2014). Integrierte Diagnose der ADHS im Erwachsenenalter – Revidierte Version (IDA-R). Iserlohn: Medice.
(2015). Trauma-Erfahrungen und sexueller Missbrauch bei ADHS. Zeitschrift für Psychiatrie, Psychologie und Psychotherapie, 63, 53–57.
(2013). Das State-Trait-Ärgerausdrucks-Inventar-2 (STAXI-2). Bern: Huber.
(2009). A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. European Archives of Psychiatry and Clinical Neuroscience, 259, 120–129.
(2008). HASE–Homburger ADHS-Skalen für Erwachsene.Göttingen: Hogrefe.
(2010). Psychopathological rating scales as efficacy parameters in adult ADHD treatment investigations-benchmarking instruments for international multicentre trials. Pharmacopsychiatry, 43, 92–98.
(2005). Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. Behaviour research and therapy, 43(7), 831–842.
(1992). Wortschatztest (WST). Göttingen: Hogrefe.
(1998). The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry, 59, 22–33.
(2013). Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments. American Journal of Psychiatry, 170, 275–289.
(2009). Validation of the adult ADHD investigator symptom rating scale (AISRS). Journal of Attention Disorders, 14, 57–68.
(2003). A self-directed psychosocial intervention with minimal therapist contact for adults with attention deficit hyperactivity disorder. Clinical Psychology & Psychotherapy, 10, 93–101.
(2006). Self-regulation of slow cortical potentials: a new treatment for children with attention-deficit/hyperactivity disorder. Pediatrics, 118, e1530–e1540.
(2011). Neurofeedback in children with ADHD: specific event-related potential findings of a randomized controlled trial. Clinical Neurophysiology, 122, 942–950.
(2007). Weiss Functional Impairment Rating Scale-Self Report (WFIRS-S). Online: http://naceonline.com/AdultADHD toolkit/assessmenttools/wfirs.pdf